CYP2C19 and COVID-19: Wang et al. reported that the voriconazole concentration may be greater or lower in patients with COVID-19 when coadministered with nirmatrelvir/ritonavir, and the difference may be attributed to polymorphisms of the CYP2C19 genotype (Wang et al., 2023).